AACC: Better Quality and Patient-Friendliness Needed in Direct Testing
|
By LabMedica International staff writers Posted on 27 Jul 2015 |
In a new position statement on direct-to-consumer (DTC) laboratory testing, the American Association for Clinical Chemistry (AACC; Washington DC, USA) emphasizes the need for patient-friendly reports and for sufficient transparency about quality of tests and results.
DTC testing allows people to order medical tests directly from a lab, without going through their healthcare provider. Noting the paradigm shift among consumers seeking greater control over their own healthcare, AACC has issued a position statement that emphasizes DTC test results must be accurate and easily understood—an area where laboratory medicine professionals play a vital role.
State laws have limited to physicians the ordering of lab tests, but as people have become more engaged in managing their own healthcare, this model has begun to change. Currently, 37 states and the District of Columbia permit consumers to order some or all of their laboratory tests without involvement of a physician. Individuals can also buy over-the-counter test kits or get laboratory services from non-traditional settings such as retail centers. These DTC lab tests can provide invaluable information to individuals about their health status in a timely and convenient manner. However, many healthcare providers and policymakers are concerned that some of these tests may be of questionable quality and value, or that consumers might not have enough background knowledge to make sound decisions based on their test results.
To enhance patient benefit, AACC urges the Centers for Medicare and Medicaid Services and the US Food and Drug Administration (FDA) to require that DTC testing providers disclose sufficient information about their products and services, enabling consumers to make well-informed decisions. These providers should provide: user-friendly descriptions of risks, benefits, and limitations of all tests offered; clear and understandable reports of test results, with enough information to assist in decision-making; prominent instructions to contact a qualified healthcare provider with any questions or concerns; and a comprehensive, public listing of tests offered and prices charged.
Laboratory medicine professionals are integral to this consumer-driven process. AACC encourages lab professionals to collaborate with federal agencies to inform the public about the costs, benefits, interpretation, and limitations of DTC tests. Likewise, consumers should consult qualified professionals in making decisions about their healthcare.
“DTC laboratory testing is a key element of ongoing efforts to empower people in decisions affecting their healthcare,” said AACC CEO Janet B. Kreizman, “AACC supports expanding consumer access to high-quality DTC testing services, and urges policymakers to ensure that these services have demonstrated clinical validity and utility and make a positive impact on patient outcomes.”
Related Links:
American Association for Clinical Chemistry (AACC)
AACC position statement on direct-to-consumer testing
DTC testing allows people to order medical tests directly from a lab, without going through their healthcare provider. Noting the paradigm shift among consumers seeking greater control over their own healthcare, AACC has issued a position statement that emphasizes DTC test results must be accurate and easily understood—an area where laboratory medicine professionals play a vital role.
State laws have limited to physicians the ordering of lab tests, but as people have become more engaged in managing their own healthcare, this model has begun to change. Currently, 37 states and the District of Columbia permit consumers to order some or all of their laboratory tests without involvement of a physician. Individuals can also buy over-the-counter test kits or get laboratory services from non-traditional settings such as retail centers. These DTC lab tests can provide invaluable information to individuals about their health status in a timely and convenient manner. However, many healthcare providers and policymakers are concerned that some of these tests may be of questionable quality and value, or that consumers might not have enough background knowledge to make sound decisions based on their test results.
To enhance patient benefit, AACC urges the Centers for Medicare and Medicaid Services and the US Food and Drug Administration (FDA) to require that DTC testing providers disclose sufficient information about their products and services, enabling consumers to make well-informed decisions. These providers should provide: user-friendly descriptions of risks, benefits, and limitations of all tests offered; clear and understandable reports of test results, with enough information to assist in decision-making; prominent instructions to contact a qualified healthcare provider with any questions or concerns; and a comprehensive, public listing of tests offered and prices charged.
Laboratory medicine professionals are integral to this consumer-driven process. AACC encourages lab professionals to collaborate with federal agencies to inform the public about the costs, benefits, interpretation, and limitations of DTC tests. Likewise, consumers should consult qualified professionals in making decisions about their healthcare.
“DTC laboratory testing is a key element of ongoing efforts to empower people in decisions affecting their healthcare,” said AACC CEO Janet B. Kreizman, “AACC supports expanding consumer access to high-quality DTC testing services, and urges policymakers to ensure that these services have demonstrated clinical validity and utility and make a positive impact on patient outcomes.”
Related Links:
American Association for Clinical Chemistry (AACC)
AACC position statement on direct-to-consumer testing
Latest AACC 2015 News
- Automated Molecular Diagnostics System Presented at AACC 2015
- Portable Molecular Diagnostics System Unveiled At 2015 AACC
- Expanded Steroid Control Launched at the 2015 AACC Annual Meeting
- Innovative New Technology to Provide Plastic-Exterior Components with Glass Interior, Presented at AACC 2015
- Eco-Friendly Immunoassay Reagents Featured at AACC 2015
- Low Cost Point-of-Care DNA Amplification Test for Chlamydia Infection Demonstrated at the 2015 AACC Annual Meeting
- Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting
- State-of-the-Art Automated Laboratory Systems Highlighted at the 2015 AACC Annual Meeting
- Siemens Showcases Multiple New IVD Solutions at AACC 2015
- New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015
- Diagnostic Test that Measures Active Renin in Hypertension Displayed at the 2015 AACC Annual Meeting
- Hair Testing May Offer Insights into Asthma-Related Complications in Pregnancy
- Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring
- CE Marking of Theranostic Monitoring Test Announced at 2015 AACC Annual Meeting
- Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting
- Clinical Chemistry Instruments and Reagents Under Scrutiny at the 2015 AACC Annual Meeting
Channels
Clinical Chemistry
view channel
Rapid Ferritin Test Enables Iron Deficiency Detection at the Point of Care
Iron deficiency is one of the world’s most common nutritional disorders and can be difficult to diagnose where access to laboratories and trained personnel is limited. Women and children in low-resource... Read more
Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read more
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
New Collaboration Advances Precision Oncology Screening for Lung Cancer in Japan
Molecular profiling is central to precision oncology in lung cancer, but tissue samples can be limited and minimally invasive approaches are often preferable. Liquid biopsy enables blood-based genomic... Read more








